Last Updated: May 21, 2026

Suppliers and packagers for BIKTARVY


✉ Email this page to a colleague

« Back to Dashboard


BIKTARVY

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Gilead Sciences Inc BIKTARVY bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 210251 NDA A-S Medication Solutions 50090-6247-0 30 TABLET in 1 BOTTLE, PLASTIC (50090-6247-0) 2018-02-07
Gilead Sciences Inc BIKTARVY bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 210251 NDA Gilead Sciences, Inc. 61958-2501-1 30 TABLET in 1 BOTTLE, PLASTIC (61958-2501-1) 2018-02-07
Gilead Sciences Inc BIKTARVY bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 210251 NDA Gilead Sciences, Inc. 61958-2501-2 7 TABLET in 1 BOTTLE, PLASTIC (61958-2501-2) 2018-02-07
Gilead Sciences Inc BIKTARVY bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 210251 NDA Gilead Sciences, Inc. 61958-2501-3 30 TABLET in 1 BLISTER PACK (61958-2501-3) 2018-02-07
Gilead Sciences Inc BIKTARVY bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 210251 NDA Gilead Sciences, Inc. 61958-2501-5 30 TABLET in 1 BLISTER PACK (61958-2501-5) 2018-02-07
Gilead Sciences Inc BIKTARVY bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 210251 NDA Gilead Sciences, Inc. 61958-2505-1 30 TABLET in 1 BOTTLE, PLASTIC (61958-2505-1) 2021-10-07
Gilead Sciences Inc BIKTARVY bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 210251 NDA Gilead Sciences, Inc. 61958-2506-1 30 TABLET in 1 BOTTLE, PLASTIC (61958-2506-1) 2024-10-08
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers and packagers for BIKTARVY

Last updated: April 25, 2026

Who Supplies BIKTARVY’s Drug Substance, Drug Product, and Key Materials?

BIKTARVY is a fixed-dose combination (FDC) antiretroviral regimen containing bictegravir (BIC), emtricitabine (FTC), and tenofovir alafenamide (TAF). The formulation is marketed by Gilead Sciences in the US. The supply chain for such products typically spans (1) active pharmaceutical ingredients (APIs) and (2) finished-dose manufacturing through contract manufacturing organizations (CMOs).

However, no authoritative supplier list (named manufacturers for each API and the finished-dose site(s)) is provided in the information available in this session, and producing names would risk inaccuracy.

What’s directly supportable from available information

  • Product: BIKTARVY (bictegravir / emtricitabine / tenofovir alafenamide)
  • Marketing authorization holder (US): Gilead Sciences (as brand owner and commercial sponsor)
  • Component identities:
    • Bictegravir
    • Emtricitabine
    • Tenofovir alafenamide

What cannot be stated accurately here

  • Named API suppliers for bictegravir, emtricitabine, and tenofovir alafenamide
  • Named finished-dose suppliers (tablet/capsule manufacturing and packaging sites)
  • Named suppliers of key excipients, coating systems, or blister/bottle packaging for BIKTARVY

BIKTARVY Supply Chain Map (What would be populated with verified sources)

Supply layer Item category Specific items for BIKTARVY
APIs Drug substances Bictegravir, Emtricitabine, Tenofovir alafenamide
Finished product Dosage form manufacturing BIKTARVY tablets + packaging
Inputs Excipients, materials Tablet excipients, coating components, packaging materials

Key Takeaways

  • BIKTARVY is a 3-drug FDC: bictegravir + emtricitabine + tenofovir alafenamide.
  • Gilead Sciences is the US brand sponsor, but named supplier/manufacturer lists for APIs and finished-dose manufacturing are not present in the available data here.
  • Any named supplier claims without verified regulatory or corporate documentation would not meet accuracy requirements.

FAQs

  1. Who supplies BIKTARVY?
    The brand is marketed by Gilead Sciences, but specific contracted supplier/manufacturing site names are not provided in the available information here.

  2. Which APIs are in BIKTARVY?
    Bictegravir, emtricitabine, and tenofovir alafenamide.

  3. Are BIKTARVY APIs sourced from the same supplier?
    Fixed-dose products often use multiple API sources, but specific supplier assignments are not available here.

  4. Who manufactures the finished BIKTARVY tablets?
    Finished-dose manufacturing is performed by Gilead and/or contract manufacturers, but named manufacturing sites are not available in the available information here.

  5. Where can verified supplier lists be found?
    Supplier/manufacturing details are typically disclosed through regulatory filings and product labeling, but no such source text is included in this session.

References

[1] No citable sources were provided in the available input for named BIKTARVY suppliers (API or finished-dose).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.